Is silent ischemia a treatable risk factor in patients with angina pectoris?
Silent myocardial ischemia is increasingly recognized as a common phenomenon in a variety of populations with coronary artery disease. In patients with angina pectoris, this condition has been recognized during either exercise stress testing or ambulatory monitoring when ischemic-type ST-segment shifts occur without symptoms. Although more information is clearly needed, available data suggest an important independent relation between ambulant ischemia, most of which is silent, and adverse outcome. Other studies show that currently available antianginal agents can prevent or modify symptomatic as well as silent ischemic episodes. Several reports indicate that when these agents are prescribed to control symptomatic ischemic episodes, silent ischemia may continue to occur. Yet, when antianginal drugs are used either alone or in combination in those with recurrent silent ischemia, both the frequency and duration of the silent ischemic episodes are greatly reduced. To date, however, no data are yet available on the impact on outcome of a strategy directed at detecting and treating silent ischemia. Until this information is available, more attention should be focused on identifying and adequately controlling ischemia rather than on simply managing chest pain.
Department of Medicine, University of Florida, Gainesville 32610.
C J
CJ
Pepine
D000787:Angina Pectoris / Q000150:complications*; D000789:Angina, Unstable / Q000503:physiopathology; D003327:Coronary Disease / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D005544:Forecasting; D006801:Humans; D011379:Prognosis; D012307:Risk Factors; D013997:Time Factors